Evidence map›Paper›PMID 37570604›Full record

ArticleMolecules (Basel, Switzerland)2023

Assessment of Purity, Stability, and Pharmacokinetics of NGP-1, a Novel Prodrug of GS441254 with Potential Anti-SARS-CoV-2 Activity, Using Liquid Chromatography.

Chen Sun, Bo Liu, Fengzhi Zhou, Qianqian Zheng, Chunmei Dai, Wei Wei, Guochao Liao, Yuqi Sun

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Chen SunSchool of Pharmacy, Jinzhou Medical University, Jinzhou 121001, China.
Bo LiuSchool of Pharmacy, Jinzhou Medical University, Jinzhou 121001, China.
Fengzhi ZhouSchool of Pharmacy, Jinzhou Medical University, Jinzhou 121001, China.
Qianqian ZhengSchool of Pharmacy, Jinzhou Medical University, Jinzhou 121001, China.
Chunmei DaiSchool of Pharmacy, Jinzhou Medical University, Jinzhou 121001, China.
Wei WeiSchool of Pharmacy, Jinzhou Medical University, Jinzhou 121001, China.
Guochao LiaoInternational Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou 510006, China.
Yuqi SunSchool of Pharmacy, Jinzhou Medical University, Jinzhou 121001, China.

Funding

Education Department of Liaoning province LJKZ0804
6 · The paper itself

Abstract

SARS-CoV-2 is a highly contagious and pathogenic virus that first appeared in late December 2019 and caused a global pandemic in a short period. The virus is a single-stranded RNA virus belonging to the Coronaviridae family. Numerous treatments have been developed and tested in response to the pandemic, particularly antiviral drugs. Among them, GS441524 (GS441), a nucleoside antiviral drug, has demonstrated promising results in inhibiting SARS-CoV-2. Nevertheless, the limited oral bioavailability of GS441 restricts its application to patients with the virus. In this study, a novel prodrug of GS441 (NGP-1) with an isobutyl ester and cyclic carbonate structure was designed and synthesized. Its purity and the stability in different artificial digestive juices of NGP-1 was determined with HPLC-DAD methods. The pharmacokinetics of NGP-1 and GS441 were studied in rats via gavage administration. A new LC-MS/MS method was developed to quantitatively analyze GS441 in plasma samples. The results showed that the k

Indexed as

COVID-19ProdrugsAnimalsAntiviral AgentsChromatography, LiquidRatsSARS-CoV-2Tandem Mass SpectrometryAntiviral AgentsProdrugsanti-SARS-CoV-2LC-MS/MSoral bioavailabilityprodrug of GS441524puritystability and pharmacokinetics

Identifiers

PMID37570604
PMCPMC10420250

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.